Anurag Joshi’s Post

What are #Biosimilars? Glad you asked! Biosimilars create a broader range of cost-effective alternatives to reference biologics for healthcare providers. At Teva, we work relentlessly to transform every aspect of biologic drug development to improve speed and efficiency and maximize the value of biologics. This #GlobalBiosimilarsWeek, learn how biosimilars help bring affordable medicines to patients and savings to healthcare systems. Discover more here. https://lnkd.in/dR4Utg5r #GlobalBiosimilarsWeek #biosimilars #TevaBiosimilarsUnlockingValue #Tevapharm

20 June 2024! US FDA updates draft guidance on interchangeability! FDA issued a draft guidance for industry “Considerations for Demonstrating Interchangeability with a Reference Product: Update.” This draft guidance describes considerations regarding a switching study or studies intended to support a demonstration that a biological product is interchangeable with a reference product. “The recommendations in today’s draft guidance, when finalized, will provide clarity and transparency about the FDA’s thinking and align the review and approval process with existing and emerging science,” said Sarah Yim, MD, director of the Office of Therapeutic Biologics and Biosimilars. “We have gained valuable experience reviewing both biosimilar and interchangeable biosimilar medications over the last 10 years. Both biosimilars and interchangeable biosimilars meet the same high standard of biosimilarity for FDA approval and both are as safe and effective as the reference product.” https://lnkd.in/dq25BMUr #biosimilars

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health® is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/dbbXRbud #TeamCVS

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health® is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/gHBSTDkT #TeamCVS

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health® is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/eSKejpmq #TeamCVS

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health® is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/gZZM-MBH #TeamCVS

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health® is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/eV_AnfJR #TeamCVS

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health® is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/dUYk4wrE #TeamCVS

#DidYouKnow that by 2027, biologic drug spend will reach $1.5T? Of the U.S. biologics market, only 1-3% of the patient population is treated by biologics, but it still accounts for 46% of the total drug spend. That’s why CVS Health® is taking steps to encourage the adoption of high-quality, affordable medications, including biosimilar drugs – which have no clinically meaningful differences from an existing FDA-approved reference product. See how biosimilars offer a more affordable option in our #Biosimilars report: https://lnkd.in/gJYhaRFA #TeamCVS